Walleye Capital LLC Has $135,000 Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

Walleye Capital LLC trimmed its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Rating) by 32.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,000 shares of the company’s stock after selling 8,196 shares during the period. Walleye Capital LLC’s holdings in Edgewise Therapeutics were worth $135,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Amalgamated Bank acquired a new stake in Edgewise Therapeutics during the first quarter worth about $61,000. SG Americas Securities LLC bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $90,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $96,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Edgewise Therapeutics in the first quarter worth about $125,000. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $175,000.

Analyst Ratings Changes

A number of research firms have recently commented on EWTX. Royal Bank of Canada dropped their target price on shares of Edgewise Therapeutics from $31.00 to $29.00 and set an “outperform” rating for the company in a report on Friday, November 4th. The Goldman Sachs Group cut shares of Edgewise Therapeutics from a “neutral” rating to a “sell” rating and set a $5.00 target price for the company. in a report on Wednesday, August 24th.

Insider Activity at Edgewise Therapeutics

In other Edgewise Therapeutics news, Director Peter A. Thompson acquired 484,496 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The stock was acquired at an average price of $10.32 per share, for a total transaction of $4,999,998.72. Following the acquisition, the director now directly owns 13,981,952 shares in the company, valued at $144,293,744.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Peter A. Thompson purchased 484,496 shares of the stock in a transaction on Friday, September 16th. The stock was purchased at an average price of $10.32 per share, for a total transaction of $4,999,998.72. Following the acquisition, the director now owns 13,981,952 shares in the company, valued at $144,293,744.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel John R. Moore sold 4,730 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $9.76, for a total transaction of $46,164.80. Following the transaction, the general counsel now owns 3,000 shares of the company’s stock, valued at approximately $29,280. The disclosure for this sale can be found here. 37.05% of the stock is owned by company insiders.

Edgewise Therapeutics Price Performance

Shares of NASDAQ EWTX opened at $10.00 on Monday. The company has a 50 day simple moving average of $9.94 and a 200 day simple moving average of $9.14. The firm has a market cap of $632.14 million, a PE ratio of -8.20 and a beta of -0.23. Edgewise Therapeutics, Inc. has a 1 year low of $5.41 and a 1 year high of $22.98.

Edgewise Therapeutics Profile

(Get Rating)

Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.

Featured Stories

Want to see what other hedge funds are holding EWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Rating).

Institutional Ownership by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.